Bioheart, Inc. Announces Mike Tomas, President/CEO, Has Been Chosen As An Honoree For Emerge Americas Techweek100 Miami 2014

SUNRISE, FL--(Marketwired - March 25, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomás, President and CEO, has been named as one of the top 100 technology leaders on eMerge Americas Techweek100 Miami 2014. (http://techweek.com/miami/techweek100/).

The Techweek100 is a list of the top 100 technology leaders and influencers of fast-growing technology companies, key enablers of the digital ecosystem, creators of new technologies, and other innovators that make important contributions to their field. The list identifies the key leaders and innovators in the tech community who have made a significant impact on business and technology in South Florida.

“It is truly an honor to be included on the list of South Florida’s outstanding tech innovators,” said Tomas, Bioheart’s president and CEO. “We are excited to showcase Bioheart’s groundbreaking technology during Techweek100.”

The eMerge Americas Techweek100 Miami 2014 list is chosen by the South Florida community and the team at eMerge Techweek. Their mission is to showcase, celebrate and enable emerging innovation ecosystems in the great cities of America. The eMerge Americas Miami Techweek is a weeklong celebration that will take place on May 1-7 at the Miami Beach Convention Center.

About Bioheart, Inc.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart’s goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.